Literature DB >> 22112290

Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer.

Lee W Jones1, Whitney E Hornsby, Amy Goetzinger, Lindsay M Forbes, Emily L Sherrard, Morten Quist, Amy T Lane, Miranda West, Neil D Eves, Margaret Gradison, April Coan, James E Herndon, Amy P Abernethy.   

Abstract

BACKGROUND: To investigate the prognostic importance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Using a prospective design, 118 consecutive participants with histologically confirmed metastatic (inoperable) NSCLC and Eastern Cooperative Oncology group (ECOG) 0-3 completed a six-minute walk test to assess functional capacity and questionnaire that assessed self-reported exercise behavior. Cox proportional models were used to estimate the risk of all-cause mortality according to six-minute walk distance (6MWD) (<358.5m, 358.5-450 m, ≥450 m) and exercise behavior (MET-hrswk(-1)) categories with adjustment for important covariates.
RESULTS: Median follow-up was 26.6 months; 77 deaths were reported during this period. Functional capacity was an independent predictor of survival (P(trend)=0.003) and added incremental prognostic value beyond that provided by PS plus other traditional markers of prognosis (P(trend)=0.025). Compared with patients achieving a 6MWD <358.5m, the adjusted hazard ratio (HR) for all-cause mortality was 0.61 (95% CI, 0.34-1.07) for a 6MWD of 358.5-450 m, and 0.48 (95% CI, 0.24-0.93) for a 6MWD >450 m. In unadjusted analysis, there was a borderline significant effect of exercise behavior on survival (p=0.052). Median survival was 12.89 months (95% CI, 9.11-21.05 months) for those reporting <9MET-hrswk(-1) compared with 25.63 months (95% CI, 11.28 to ∞ months) for those reporting ≥9MET-hrswk(-1).
CONCLUSIONS: Functional capacity is a strong independent predictor of survival in advanced NSCLC that adds to the prediction of survival beyond traditional risk factors. This parameter may improve risk stratification and prognostication in NSCLC.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22112290      PMCID: PMC3615546          DOI: 10.1016/j.lungcan.2011.10.009

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  36 in total

1.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

2.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

3.  The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis.

Authors:  Christopher J Lettieri; Steven D Nathan; Robert F Browning; Scott D Barnett; Shahzad Ahmad; Andrew F Shorr
Journal:  Respir Med       Date:  2006-03-20       Impact factor: 3.415

Review 4.  Cardiorespiratory exercise testing in clinical oncology research: systematic review and practice recommendations.

Authors:  Lee W Jones; Neil D Eves; Mark Haykowsky; Anil A Joy; Pamela S Douglas
Journal:  Lancet Oncol       Date:  2008-08       Impact factor: 41.316

5.  Safety and feasibility of a combined exercise intervention for inoperable lung cancer patients undergoing chemotherapy: a pilot study.

Authors:  Morten Quist; Mikael Rørth; Seppo Langer; Lee W Jones; Jørgen H Laursen; Helle Pappot; Karl Bang Christensen; Lis Adamsen
Journal:  Lung Cancer       Date:  2011-08-03       Impact factor: 5.705

6.  4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index.

Authors:  François Blanchon; Michel Grivaux; Bernard Asselain; François-Xavier Lebas; Jean-Pierre Orlando; Jacques Piquet; Mahmoud Zureik
Journal:  Lancet Oncol       Date:  2006-10       Impact factor: 41.316

7.  Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing.

Authors:  Lee W Jones; Rachel-Rose Cohen; Stephanie K Mabe; Miranda J West; Annick Desjardins; James J Vredenburgh; Allan H Friedman; David A Reardon; Emily Waner; Henry S Friedman
Journal:  J Neurooncol       Date:  2009-02-11       Impact factor: 4.130

8.  The 6-min walk distance, peak oxygen uptake, and mortality in COPD.

Authors:  Claudia G Cote; Victor Pinto-Plata; Kyra Kasprzyk; Luis J Dordelly; Bartolome R Celli
Journal:  Chest       Date:  2007-10-09       Impact factor: 9.410

Review 9.  Exercise therapy across the lung cancer continuum.

Authors:  Lee W Jones; Neil D Eves; Emily Waner; Anil A Joy
Journal:  Curr Oncol Rep       Date:  2009-07       Impact factor: 5.075

10.  Effects of presurgical exercise training on cardiorespiratory fitness among patients undergoing thoracic surgery for malignant lung lesions.

Authors:  Lee W Jones; Carolyn J Peddle; Neil D Eves; Mark J Haykowsky; Kerry S Courneya; John R Mackey; Anil A Joy; Vikaash Kumar; Timothy W Winton; Tony Reiman
Journal:  Cancer       Date:  2007-08-01       Impact factor: 6.860

View more
  75 in total

1.  Imaging skeletal muscle volume, density, and FDG uptake before and after induction therapy for non-small cell lung cancer.

Authors:  M D Goncalves; S Taylor; D F Halpenny; E Schwitzer; S Gandelman; J Jackson; A Lukose; A J Plodkowski; K S Tan; M Dunphy; L W Jones; R J Downey
Journal:  Clin Radiol       Date:  2018-01-06       Impact factor: 2.350

Review 2.  Effects and potential mechanisms of exercise training on cancer progression: a translational perspective.

Authors:  Allison S Betof; Mark W Dewhirst; Lee W Jones
Journal:  Brain Behav Immun       Date:  2012-05-17       Impact factor: 7.217

3.  The nexus of functional exercise capacity with health-related quality of life in lung cancer: how closely are they related?

Authors:  Catherine L Granger; Lara Edbrooke; Linda Denehy
Journal:  Ann Transl Med       Date:  2018-12

4.  Performance Status in Cancer: Not Broken, But Time for an Upgrade?

Authors:  Jessica M Scott; Guro Stene; Elisabeth Edvardsen; Lee W Jones
Journal:  J Clin Oncol       Date:  2020-06-25       Impact factor: 44.544

5.  Short and long-term impairments of cardiopulmonary fitness level in previous childhood cancer cases: a systematic review.

Authors:  Vesile Yildiz Kabak; Patrick Calders; Tulin Duger; Jibril Mohammed; Eric van Breda
Journal:  Support Care Cancer       Date:  2018-09-25       Impact factor: 3.603

6.  Daily diary study of hope, stigma, and functioning in lung cancer patients.

Authors:  Laurie E Steffen; Kevin E Vowles; Bruce W Smith; Gregory N Gan; Martin J Edelman
Journal:  Health Psychol       Date:  2017-11-27       Impact factor: 4.267

7.  Cardiopulmonary exercise testing prior to myeloablative allo-SCT: a feasibility study.

Authors:  C R Kelsey; J M Scott; A Lane; E Schwitzer; M J West; S Thomas; J E Herndon; M G Michalski; M E Horwitz; T Hennig; L W Jones
Journal:  Bone Marrow Transplant       Date:  2014-07-28       Impact factor: 5.483

Review 8.  Running away from side effects: physical exercise as a complementary intervention for breast cancer patients.

Authors:  S Casla; P Hojman; I Márquez-Rodas; S López-Tarruella; Y Jerez; R Barakat; M Martín
Journal:  Clin Transl Oncol       Date:  2014-06-04       Impact factor: 3.405

9.  Evaluation of pedometry as a patient-centered outcome in patients undergoing hematopoietic cell transplant (HCT): a comparison of pedometry and patient reports of symptoms, health, and quality of life.

Authors:  Antonia V Bennett; Bryce B Reeve; Ethan M Basch; Sandra A Mitchell; Mathew Meeneghan; Claudio L Battaglini; Abbie E Smith-Ryan; Brett Phillips; Thomas C Shea; William A Wood
Journal:  Qual Life Res       Date:  2015-11-17       Impact factor: 4.147

10.  Using Perceived Self-efficacy to Improve Fatigue and Fatigability In Postsurgical Lung Cancer Patients: A Pilot Randomized Controlled Trial.

Authors:  Amy J Hoffman; Ruth Ann Brintnall; Barbara A Given; Alexander von Eye; Lee W Jones; Jean K Brown
Journal:  Cancer Nurs       Date:  2017 Jan/Feb       Impact factor: 2.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.